JNJ

170.73

-0.23%↓

ABBV

198.59

+0.8%↑

AZN

74.43

-0.13%↓

NVS

117.78

-0.02%↓

ABT

130.77

+0.52%↑

JNJ

170.73

-0.23%↓

ABBV

198.59

+0.8%↑

AZN

74.43

-0.13%↓

NVS

117.78

-0.02%↓

ABT

130.77

+0.52%↑

JNJ

170.73

-0.23%↓

ABBV

198.59

+0.8%↑

AZN

74.43

-0.13%↓

NVS

117.78

-0.02%↓

ABT

130.77

+0.52%↑

JNJ

170.73

-0.23%↓

ABBV

198.59

+0.8%↑

AZN

74.43

-0.13%↓

NVS

117.78

-0.02%↓

ABT

130.77

+0.52%↑

JNJ

170.73

-0.23%↓

ABBV

198.59

+0.8%↑

AZN

74.43

-0.13%↓

NVS

117.78

-0.02%↓

ABT

130.77

+0.52%↑

Search

Allogene Therapeutics Inc

Закрыт

СекторЗдравоохранение

1.11 0.91

Обзор

Изменение цены акций

24 ч

Текущая

Мин.

1.07

Макс.

1.15

Ключевые показатели

By Trading Economics

Доход

206K

-60M

Рентабельность продаж

272,450

Сотрудники

226

EBITDA

-302K

-56M

Рекомендации

By TipRanks

Рекомендации

Активная покупка

Прогноз на 12 месяцев

+647.27% upside

Дивиденды

By Dow Jones

Следующий отчет о доходах

6 авг. 2025 г.

Рыночная статистика

By TradingEconomics

Рыночная капитализация

-15M

241M

Предыдущая цена открытия

0.2

Предыдущая цена закрытия

1.11

Новостные настроения

By Acuity

19%

81%

36 / 374 Рейтинг в Healthcare

Техническая оценка

By Trading Central

Уверенность

Very Strong Bearish Evidence

Allogene Therapeutics Inc График

Прошлые результаты не являются надежным индикатором будущих результатов.

Связанные новости

5 авг. 2025 г., 23:11 UTC

Отчет

Australia's REA Hikes Dividend as Annual Profit Rises 23% -- Update

5 авг. 2025 г., 22:45 UTC

Отчет

Australia's REA Hikes Dividend as Annual Profit Rises 23%

5 авг. 2025 г., 22:39 UTC

Отчет

Great-West Lifeco Logs Lower 2Q Profit

5 авг. 2025 г., 21:32 UTC

Отчет

Coupang Posts Higher 2Q Sales Due to Customer Growth

6 авг. 2025 г., 00:00 UTC

Приобретения, слияния, поглощения

NFL to Take 10% Stake in Disney's ESPN -- WSJ

6 авг. 2025 г., 00:00 UTC

Приобретения, слияния, поглощения

The NFL Is Taking a 10% Stake in Disney's ESPN -- WSJ

6 авг. 2025 г., 00:00 UTC

Приобретения, слияния, поглощения

Disney to Take Control of NFL Network as Part of Agreement -- WSJ

6 авг. 2025 г., 00:00 UTC

Приобретения, слияния, поглощения

Disney, NFL Strike Wide-Reaching Media-Asset Deal -- WSJ

5 авг. 2025 г., 23:48 UTC

Обсуждения рынка

Nikkei May Decline Amid U.S. Economic Uncertainty -- Market Talk

5 авг. 2025 г., 23:40 UTC

Обсуждения рынка

Gold Edges Higher, Supported by Fed Rate-Cut Hopes -- Market Talk

5 авг. 2025 г., 23:19 UTC

Обсуждения рынка

Lindian Deal With Iluka Demonstrates Kangankunde Project Appeal -- Market Talk

5 авг. 2025 г., 23:03 UTC

Обсуждения рынка
Отчет

Advanced Micro Devices' Data-Center Story Seen as Promising -- Market Talk

5 авг. 2025 г., 22:22 UTC

Отчет

REA: Expectation of More Interest-Rate Cuts Likely to Support Buyer Demand>REA.AU

5 авг. 2025 г., 22:21 UTC

Отчет

REA Expects FY26 Listing Volumes Broadly Flat on FY25>REA.AU

5 авг. 2025 г., 22:20 UTC

Отчет

REA Expects September-Quarter Listings to Be Down on Year>REA.AU

5 авг. 2025 г., 22:18 UTC

Отчет

REA July 2025 New Residential Listings Down 8% on Year>REA.AU

5 авг. 2025 г., 22:17 UTC

Отчет

REA FY25 Australian Residential Listings Up 1% on Year>REA.AU

5 авг. 2025 г., 22:17 UTC

Отчет

REA FY25 India Revenue A$129M Vs. A$103M>REA.AU

5 авг. 2025 г., 22:16 UTC

Отчет

REA FY25 Core Australia Revenue A$1.54B Vs. A$1.35B>REA.AU

5 авг. 2025 г., 22:16 UTC

Отчет

REA FY25 Core Operations Net Profit A$564.4M Vs. A$460.5M>REA.AU

5 авг. 2025 г., 22:15 UTC

Отчет

REA Group FY25 Ebitda A$969.2M Vs. A$824.8M>REA.AU

5 авг. 2025 г., 22:13 UTC

Отчет

REA Group Raises Dividend to A$1.38 Vs. A$1.02 >REA.AU

5 авг. 2025 г., 22:13 UTC

Отчет

REA Group FY25 Rev A$1.67B Vs. A$1.45B >REA.AU

5 авг. 2025 г., 22:12 UTC

Отчет

REA FY25 Core Operations Net Profit A$564.4M Vs, A$460.5M>REA.AU

5 авг. 2025 г., 22:12 UTC

Отчет

REA Group FY25 Net A$677.9M Vs. Net A$302.8M >REA.AU

5 авг. 2025 г., 21:58 UTC

Отчет

Novo Nordisk's Earnings Come After a Dramatic Guidance Cut. What to Look for Now. -- Barrons.com

5 авг. 2025 г., 21:30 UTC

Отчет

AMD Gives a Strong Outlook. Why the Stock Is Falling. -- Barrons.com

5 авг. 2025 г., 21:26 UTC

Отчет

AMD CEO Expects Embedded Segment to Return to Sequential Growth in Back Half of 2025

5 авг. 2025 г., 21:23 UTC

Отчет

AMD CEO Sees Strong Customer Interest in MI400 Series for Large-Scale Deployments

5 авг. 2025 г., 21:17 UTC

Отчет

AMD Expects Steep Production Ramp for MI350 Series in Back Half of Year, CEO Says

Сравнение c конкурентами

Изменение цены

Allogene Therapeutics Inc Прогноз

Целевая цена

By TipRanks

647.27% рост

Прогноз на 12 месяцев

Средняя 8.22 USD  647.27%

Максимум 14 USD

Минимум 4 USD

Основано на мнении 14 аналитиков Wall Street, спрогнозировавших целевые цены для Allogene Therapeutics Inc на следующие 12 месяцев – Данные за последние 3 месяца.

Консенсус по рейтингу

By TipRanks

Активная покупка

14 ratings

11

Покупка

3

Удержание

0

Продажа

Техническая оценка

By Trading Central

1.18 / 1.69Поддержка и Сопротивление

Краткосрочная

Very Strong Bearish Evidence

Среднесрочная

Weak Bullish Evidence

Долгосрочная

Weak Bearish Evidence

Настроения

By Acuity

36 / 374Рейтинг в Здравоохранение

Новостные настроения

Сильные свидетельства восходящего тренда

Волатильность

Ниже среднего

Объем новостей (RCV)

Выше среднего

Финансовые показатели

Расходы на продажи и администрирование

Операционные расходы

Прибыль до уплаты налогов

Продажи

Себестоимость реализации

Валовая прибыль от продаж

Процентные расходы по долгу

EBITDA

Операционная прибыль

$

О компании Allogene Therapeutics Inc

Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL). The company also develops cemacabtagene ansegedleucel, an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma; and is in Phase 1b clinical trial for the treatment of chronic lymphocytic leukemia. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase 1 clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO-316, an allogeneic CAR T cell product candidate that is in Phase 1 clinical trial for the treatment of advanced or metastatic RCC; ALLO-329 for the treatment of certain autoimmune diseases; DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors; and Claudin 18.2 for the treatment of gastric and pancreatic cancer. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates; and a strategic partnership with Foresight Diagnostics to develop MRD-based In-Vitro Diagnostic for use in ALPHA3. The company was incorporated in 2017 and is headquartered in South San Francisco, California.